Vaccines
Excerpt from the Press Release: ATHENS, Ga. and LOS GATOS, Calif., July 21, 2022 /PRNewswire/ — Blue Lake Biotechnology, Inc., a clinical-stage biotechnology company developing vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector, today announced the enrollment of the first participant in a Phase 1 clinical trial of their intranasal BLB-201 vaccine for RSV (respiratory syncytial virus)…
Read More
BOSTON, July 06, 2022 (GLOBE NEWSWIRE) — Elicio Therapeutics, a clinical stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced that it presented preclinical data demonstrating its Amphiphile (AMP) platform adjuvant AMP-CpG combined with cell surface-associated viral protein EBV gp350 and EBVpoly protein, which elicits a…
Read More
New Preclinical Data Demonstrate Two of Vaxart’s COVID-19 Vaccine Candidates Protect Against Omicron
Results provide additional support for the cross-reactivity of Vaxart’s oral vaccine candidates Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT) today reported positive preliminary preclinical data demonstrating that two COVID-19 vaccine candidates targeting either the SARS-CoV-2 spike (S) protein for Wuhan or S protein…
Read More
The Phase 3 ACTIV-1 Immune Modulators study was sponsored by the National Institutes of Health as part of the ACTIV initiative Orencia was one of two immune modulators that improved survival for people hospitalized with COVID-19 Safety profile of Orencia remained consistent, with no new safety signals reported Excerpt from the Press Release: PRINCETON, N.J.–(BUSINESS…
Read More
Up to 600 volunteers will participate in an AKS-452 COVID booster study in the Netherlands to investigate boosting the immune response of those previously vaccinated with EMA-registered vaccines AKS-452 has shown the ability to successfully neutralize the omicron variant of the SARS-CoV-2 virus Shelf stable at 25° Celsius (77° Fahrenheit) for at least 6 months,…
Read More
Proprietary, Formulated DNA Plasmid Vaccine Candidate Shows NeutralizingActivity Against 2 Strains of the COVID-19 Virus The Goal to Provide Broader Range Protection within a Highly Flexible PlatformAppears to Show Promise Excerpt from the Press Release: LAWRENCEVILLE, N.J., April 21, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today presented…
Read More
Excerpt from the Press Release: SAN DIEGO, Feb. 11, 2022 /PRNewswire/ — Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP) is embarking on a development program to commercialize its modified mRNA anti-cancer vaccine targeting the Survivin protein. In the first phase of the development program, Regen will design and have experiments carried out that will form the initial…
Read More
New agreement paves the way for better mouse models to study how the human immune system fights SARS-CoV-2 Excerpt from the Press Release: LA JOLLA, CA—Scientists at La Jolla Institute for Immunology (LJI) and Charles River Laboratories International, Inc., are launching a new project to uncover exactly how different cells in the human immune system…
Read More
HiFiViral Solution helps to accelerate understanding of the Omicron variant, providing information that is important to public health response Excerpt from the Press Release: MENLO PARK, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) — PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate, long-read sequencing technology, today announced that its new HiFiViral SARS-CoV-2 solution has successfully sequenced…
Read More Researchers around the world can utilize the synthetic genome to produce virus to test strain-specific diagnostics, monoclonal antibody treatments, small-molecule therapies, or new vaccines against the highly transmissible variant Excerpt from the Press Release: SAN DIEGO, Dec. 23, 2021 (GLOBE NEWSWIRE) — Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems,…
Read More